(R)-[1-(4-氨基苯基)乙基]氨基甲酸叔丁酯 | 262368-44-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-[1-(4-氨基苯基)乙基]氨基甲酸叔丁酯
• 中文别名: 叔丁基(R)-(1-(4-氨基苯基)乙基氨基甲酸酯
• 英文名称: (R)-[1-(4-aminophenyl)ethyl]carbamic acid tert-butyl ester
• 英文别名: (R)-[1-(4-aminophenyl)ethyl]carbamic acid t-butyl ester；(R)-tert-butyl 1-(4-aminophenyl)ethylcarbamate；(R)-[1-(4-Amino-phenyl)-ethyl]-carbamic acid tert-butyl ester；tert-butyl N-[(1R)-1-(4-aminophenyl)ethyl]carbamate
• CAS: 262368-44-5
• 化学式: C₁₃H₂₀N₂O₂
• 分子量: 236.314
• InChiKey: COSXQRGJLFEFGJ-SECBINFHSA-N

物化性质

• 沸点：
  390.5±25.0 °C(Predicted)
• 密度：
  1.073±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  64.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (R)-[1-(4-氨基苯基)乙基]氨基甲酸叔丁酯 在 三氟乙酸 作用下， 生成 (R)-4-(1-aminoethyl)aniline
  参考文献：
  名称：

  Chain-branched 1,3-dibenzylthioureas as vanilloid receptor 1 antagonists

  摘要：

  A series of chain-branched 1,3-dibenzylthiourea derivatives were synthesized, and tested their antagonist activity against vanilloid receptor 1. Chain-branching led to a significant change in the mode of action and the potency. (R)-Methyl or ethyl-branched 1,3-dibenzylthiourea derivatives showed the most potent antagonist activity up to the IC50 value of 0.05 muM which is 10-fold more potent than capsazepine. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.066
• 作为产物：
  描述：

  (R)-α-methyl-4-nitrobenzylamine hydrochloride 在 palladium on activated charcoal 氢气 、 碳酸氢钠 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 (R)-[1-(4-氨基苯基)乙基]氨基甲酸叔丁酯
  参考文献：
  名称：

  Chain-branched 1,3-dibenzylthioureas as vanilloid receptor 1 antagonists

  摘要：

  A series of chain-branched 1,3-dibenzylthiourea derivatives were synthesized, and tested their antagonist activity against vanilloid receptor 1. Chain-branching led to a significant change in the mode of action and the potency. (R)-Methyl or ethyl-branched 1,3-dibenzylthiourea derivatives showed the most potent antagonist activity up to the IC50 value of 0.05 muM which is 10-fold more potent than capsazepine. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.01.066

文献信息

• SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH
  申请人：Luzzio Michael Joseph

  公开号：US20090054395A1

  公开（公告）日：2009-02-26

  The present invention relates to a compound of the formula I wherein R 1 to R 6 , A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

  本发明涉及一种具有以下式I的化合物 其中R 1 至R 6 ，A，B，n和m如本文所定义。这种新型磺酰胺衍生物在治疗哺乳动物（如癌症）中的异常细胞生长方面是有用的。本发明还涉及一种在治疗哺乳动物（尤其是人类）中的异常细胞生长中使用这种化合物的方法，以及含有这种化合物的药物组合物。
• 3-[3-(Piperidin-1-yl)propyl]indoles as Highly Selective h5-HT_1D Receptor Agonists
  作者：Michael G. N. Russell、Victor G. Matassa、Roy R. Pengilley、Monique B. van Niel、Bindi Sohal、Alan P. Watt、Laure Hitzel、Margaret S. Beer、Josephine A. Stanton、Howard B. Broughton、José L. Castro

  DOI：10.1021/jm9910021

  日期：1999.12.2

  5-HT(1D/1B) receptor agonists are now entering the marketplace as treatments for migraine. This paper describes the development of selective h5-HT(1D) receptor agonists as potential antimigraine agents which may produce fewer side effects. A series of 3-[3-(piperidin-1-yl)propyl]indoles has been synthesized which has led to the identification of 80 (L-772,405), a high-affinity h5-HT(1D) receptor full agonist

  几种5-HT（1D / 1B）受体激动剂目前正作为偏头痛的治疗方法进入市场。本文介绍了选择性的h5-HT（1D）受体激动剂作为潜在的偏头痛药物的发展，它可能产生较少的副作用。合成了一系列3- [3-（哌啶-1-基）丙基]吲哚，该化合物导致鉴定出80（L-772,405），这是一种具有170的高亲和力h5-HT（1D）受体全激动剂对h5-HT（1D）受体的选择性是h5-HT（1B）受体的两倍。L-772,405在一系列其他5-羟色胺和非5-羟色胺受体上也表现出非常好的选择性，并且在大鼠皮下给药后具有出色的生物利用度。因此，它构成了描述偏头痛中h5-HT（1D）受体作用的有价值的工具。
• [EN] CYCLOBUTYL CARBOXYLIC ACID DERIVATIVES<br/>[FR] DÉRIVÉS D'ACIDE CYCLOBUTYLCARBOXYLIQUE
  申请人：PFIZER

  公开号：WO2009060278A1

  公开（公告）日：2009-05-14

  The invention relates to compounds of formula (I) and to pharmaceutically acceptable salts, prodrugs, solvates or hydrates thereof. This invention also relates to a method of using such compounds in the treatment of hyperproliferative diseases and autoimmune diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

  这项发明涉及式(I)的化合物及其药用可接受的盐、前药、溶剂合物或水合物。该发明还涉及一种在哺乳动物，尤其是人类，治疗过度增殖性疾病和自身免疫疾病的方法，以及含有这种化合物的药物组合物。
• [EN] 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE DERIVATIVES AND THEIR USE AS RENIN INHIBITORS IN THE TREATMENT OF HYPERTENSION, CARDIOVASCULAR OR RENAL DISEASES<br/>[FR] DERIVES DE 7-ARYL-3,9-DIAZABICYCLO(3.3.1)NON-6-ENE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE RENINE DANS LE TRAITEMENT DE L'HYPERTENSION, DE MALADIES CARDIOVASCULAIRES OU RENALES
  申请人：ACTELION PHARMACEUTICALS LTD

  公开号：WO2003093267A1

  公开（公告）日：2003-11-13

  The invention relates to novel 3,9-diazabicyclo[3.3.1]nonene derivatives of formula (I) and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as inhibitors or renin.

  该发明涉及新型3,9-二氮杂双环[3.3.1]壬烯衍生物（I）及相关化合物，以及它们作为药物组合物中活性成分的用途。该发明还涉及相关方面，包括制备这些化合物的过程、含有这些化合物中的一个或多个的药物组合物，尤其是它们作为肾素抑制剂的用途。
• 2-Methylacrylamide as a bioisoster of thiourea group for 1,3-dibenzylthioureido TRPV1 receptor antagonists
  作者：Seol Rin Park、Juhyun Kim、Sun Young Lee、Young-Ho Park、Hee-Doo Kim

  DOI：10.1016/j.bmcl.2018.04.044

  日期：2018.6

  bioisosters, 2-methylacrylamide group was the best candidate to replace thiourea group. Compound 7c, 2-methylacrylamide analog of ATC-120, showed as potent as ATC-120 in its antagonist activity. In addition, 2-methylacrylamide analog 7e having vinyl moiety showed the most potent activity with 0.022 μM of IC50 value, indicating that thiourea group of 1,3-dibenzylthioureas could be replaced to 2-methylacrylamide

  为了用具有TRPV1拮抗剂活性的1,3-二苄基硫脲用更像药物的部分取代硫脲基团，我们基于生物等位取代在两个芳香环之间引入了一组官能团。使用新生大鼠培养的脊髓感觉神经元，通过45Ca2 +-内流试验测试了合成的1,3-二苄基硫脲生物异构体对TRPV1的拮抗活性。在测试的14种生物等排体中，2-甲基丙烯酰胺基是取代硫脲基的最佳候选者。化合物7c，ATC-120的2-甲基丙烯酰胺类似物，在其拮抗活性方面显示出与ATC-120相同的效力。此外，具有乙烯基部分的2-甲基丙烯酰胺类似物7e表现出最强的活性，IC50值为0.022μM，表明硫脲基为1，